Darryle Bullard, MD
Pulmonary Disease · Cullman, ALNPI 1245288653
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,066 of the $30,036 with a category attached, or 66.8%. Verona Pharma, Inc. accounts for 71.8% of it on its own, with 40 other manufacturers making up the rest. 2025 is the largest year on record at $23,582, more than ten times the $18 reported in 2020. Among pulmonary disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 450 payments — averaging $66.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verona Pharma, Inc.$22K
- GSK$2K
- AstraZeneca$2K
- Insmed, Inc.$462
- Grifols USA, LLC$435
- Boehringer Ingelheim$360
- plus $3K from 35 others
Across 1 payment — averaging $350,000 each. An ownership or investment interest held by the physician or an immediate family member.
- Corvista Health, Inc.$350K
What the payments were for
- Speaking & faculty fees$20,06667%
- Travel & lodging$5032%
- Food & beverage$8,87030%
- Education$5962%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,036 in reported general payments places this provider in the 95th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 428 | $388,610 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 227 | $210,356 |
| Spiriva RespimatTiotropium Bromide | 36 | $31,784 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $16,534 |
| Varenicline Tartrate | 52 | $12,103 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 263 | $11,882 |
| Azelastine Hcl | 182 | $8,829 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,308 |
| Roflumilast | 106 | $7,905 |
| Ipratropium Bromide | 73 | $3,891 |
| Fluticasone Propionate | 144 | $3,118 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,951 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 24 | $2,509 |
| Mometasone Furoate | 14 | $2,481 |
| Azithromycin | 128 | $2,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,026 | $413,452472 claims |
| AstraZenecaBreztri Aerosphere | $1,812 | $210,356227 claims |
| Boehringer IngelheimSpiriva Respimat | $360 | $31,78436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Cullman
- William SaliskiMontgomery$257K
- Emily RehbergSylacauga$166K
- Tejaswini KulkarniBirmingham$134K
- Adrian DivittorioMobile$100K
- Luther CorleyHuntsville$86K
- Peter LutzMobile$63K
- Mohammad AzamTuscaloosa$58K
- Amanda DenhamBirmingham$45K
- Bryan GarciaBirmingham$29K
- Steven RoweBirmingham$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.